Thirteen-Valent Pneumococcal Conjugate Vaccine in Children With Acute Lymphoblastic Leukemia: Protective Immunity Can Be Achieved on Completion of Treatment
- 5 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (5) , 1271-1280
Abstract
Background: Children with acute lymphoblastic leukemia (ALL) are at increased risk of developing invasive pneumococcal disease. This study describes the immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) during and after chemotherapy. Methods: Children with ALL were allocated to study groups and received a single dose of PCV13: group 1, maintenance chemotherapy; group 2, end of chemotherapy; group 3, 6 months after chemotherapy. A protective vaccine response was defined as at least 10 of 12 serotypes (or >83% of serotypes with data) achieving postvaccination serotype-specific immunoglobulin G ≥0.35 µg/mL and ≥4-fold rise, compared to prevaccination at 1 and 12 months. Results: One hundred eighteen children were recruited. Only 12.8% (5/39; 95% confidence interval [CI], 4.3%–27.4%) of patients vaccinated during maintenance (group 1) achieved a protective response at 1 month postvaccination and none had a protective response at 12 months. For group 2 patients, 59.5% (22/37; 95% CI, 42.1%–75.3%) achieved a response at 1 month and 37.9% (11/29; 95% CI, 20.7%–57.7%) maintained immunity at 12 months. For group 3 patients, 56.8% (21/37; 95% CI, 39.5%–72.9%) achieved a protective response at 1 month and 43.3% (13/30; 95% CI, 25.5%–62.6%) maintained immunity at 12 months. Conclusions: This study demonstrated that the earliest time point at which protective immunity can be achieved in children with ALL is on completion of chemotherapy. This is earlier than current recommendations and may improve protection during a period when children are most susceptible to infection. Clinical Trials Registration: EudraCT 2009-011587-11.Keywords
Funding Information
- National Institute for Health Research
- Pfizer
This publication has 35 references indexed in Scilit:
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B CellsThe Journal of Infectious Diseases, 2012
- Multilaboratory Comparison of Streptococcus pneumoniae Opsonophagocytic Killing Assays and Their Level of Agreement for the Determination of Functional Antibody Activity in Human Reference SeraClinical and Vaccine Immunology, 2011
- Serotype-specific pneumococcal antibody concentrations in children treated for acute leukaemia: Table 1Archives of Disease in Childhood, 2010
- Immunisation practices of paediatric oncology and shared care oncology consultants: A United Kingdom surveyPediatric Blood & Cancer, 2010
- Bacteria, polysaccharides, vaccines and boosting: measuring and maintaining population immunityArchives of Disease in Childhood, 2008
- Revaccination of Children after Completion of Standard Chemotherapy for Acute LeukemiaClinical Infectious Diseases, 2007
- Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimensThe Journal of Pediatrics, 2005
- Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation surveyBritish Journal of Haematology, 2002
- Vaccines and VaccinationNew England Journal of Medicine, 2001